In its latest Investment Outlook, the bank explores the opportunities and challenges facing companies, policymakers and investors. Innovation and in particular 'virtual reality' (VR) is highlighted as a key theme which goes well beyond gaming with huge potential amongst many highly-skilled, safety-critical areas. It is early days for many of the virtual reality applications and difficult to know whether the mass market will embrace VR but the report concludes that early signs are positive.

The report also addresses the advances in the pharmaceutical sector and highlights how biologics - for example AbbVie's Humira, a medication which treats rheumatoid arthritis - has proven extremely lucrative for the healthcare industry. However with healthcare systems around the world increasingly asking the industry to help reduce overall costs as part of their innovations, the focus going forward will very much be on the development of treatments and antibiotics which also serve to reduce healthcare costs.

Dickson Anderson, Head of Adam Investment, commented:

'2016 was another strong year for Adam Investment which reinforced the proven strength of our investment philosophy. I am extremely proud of this and hope that this '2017 Outlook: Our ever-changing world' helps to showcase some of our thinking for the year ahead.'

The Royal Bank of Scotland Group plc published this content on 12 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 12 January 2017 13:15:06 UTC.

Original documenthttp://www.rbs.com/news/2017/january/adam---company-launches-its-investment-outlook-2017--our-ever-ch.html

Public permalinkhttp://www.publicnow.com/view/B0946667AB7BE167962749950251971FEC5A1C47